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thrombosis (ST) segment elevation myocardial infarction
(STEMI) in the right coronary artery (RCA) 4 years ago. He
had a history of hypertension and dyslipidemia, for which
he was taking amlodipine and atorvastatin, and had smoked
one pack/day for 30 years. He had been treated with
percutaneous coronary artery intervention and received a
bare metal stent over the distal RCA (Fig. 1A, upper panel);
he was then given a recommended standard dual anti-
platelet therapy [aspirin 100 mg/day and clopidogrel
75 mg/day, an adenosine diphosphate (ADP) P2Y12 receptor
antagonist].1 He also received staged stent implantation for
the left anterior descending (LAD) artery. However, the
patient had the second STEMI over the inferior wall 2 weeks
later (Fig. 1A, middle panel). A visible large thrombus for-
mation with ST at the RCA was managed with a larger
balloon and thrombus aspiration.Conflicts of interest: All authors declare no conflicts of interest.
* Corresponding author. Institute of Clinical Medicine, National
Cheng Kung University, Tainan, Taiwan; Department of Internal
Medicine, National Cheng Kung University Hospital, 138 Sheng-Li
Road, Tainan 704, Taiwan.
E-mail address: larry@mail.ncku.edu.tw (P.-Y. Liu).
http://dx.doi.org/10.1016/j.jfma.2014.03.008
0929-6646/Copyright ª 2014, Elsevier Taiwan LLC & Formosan MedicalBecause of his frequent emergencies, we tested his
CYP2C19 genotype and found that he carried loss-of-
function alleles with CYP2C19*2 homozygotes. Moreover,
his platelet function using the VerifyNow P2Y12 Assay kit
(Stago BNL, Leiden, The Netherlands) showed poor
response to clopidogrel (P2Y12 reactivity units Z 305; nor-
mally < 235), but normal to aspirin (aspirin resistance
units Z 440; normally < 500) (Fig. 1B, point 1). To atten-
uate the patient’s high on-clopidogrel platelet reactivity,
we gave him a double dose of clopidogrel (150 mg/day)
with aspirin. Unfortunately, there was only 3% increase in
the platelet inhibition rate after 1 week (Fig. 1B, point 2).
High on-clopidogrel platelet reactivity has been shown
to be an important predictor of adverse thrombotic out-
comes.1,2 The VerifyNow P2Y12 Assay enables clinicians to
reconsider whether the treatment regimens are suitable for
complicated patients.2 In our case, adequate platelet in-
hibition could not be achieved by a higher dose of clopi-
dogrel. We did not use warfarin initially, because our
patient refused repeated blood tests, which were a
requirement for additional warfarin for ST. He suffered
from the very late ST event 3.5 years later (Fig. 1A, lowest
panel). After the third event occurred, the patient was
treated with the available new P2Y12 antagonist, ticagrelor
(90 mg bid) and aspirin (100 mg/day). His platelet function
dramatically improved 1 week after ticagrelor therapy: itAssociation. All rights reserved.
Figure 1 Clinical time course in a myocardial infarction case carrying homozygous CYP2C19*2 gene defects and repeated stent
thrombosis. (A) Electrocardiograms and angiography studies (arrows indicate the site of thrombosis or infarct related artery); (B)
effect of platelet function inhibition under adjustment with clopidogrel dosage or shift with ticagrelor measured by VerifyNow
P2Y12 kits. AZ aspirin; CZ clopidogrel; LAD Z left anterior descending artery; MI Z myocardial infarction; PCI Z percutaneous
coronary artery intervention; RCAZ right coronary artery; STZ stent thrombosis; PRUZ P2Y12 reactivity unit; inhibition rate (%) is
calculated as on-treatment reactivity divided by baseline reactivity; T Z ticagrelor.
Antiplatelet strategy for stent thrombosis by VerifyNow 1023increased from 2% to 71% (Fig. 1B, points 3e4). He
remained symptom-free after 7 months of regular follow-
ups.
Although ST is not common in Taiwan, it results in a high
mortality rate.1,3 Clopidogrel is a prodrug and needs to be
converted to the active form through hepatic enzymes. The
genetic variant defect of CYP2C19 is associated with anincreased risk of adverse clinical events, especially in the
Asian population.4 A higher dose of clopidogrel can only
reduce platelet reactivity on heterozygous CYP2C19*2 car-
riers, but not on homozygous carriers.2 Our case carried the
homozygous genetic defect; alternative agents with less
metabolic pathway dependency are reasonable. Newer
P2Y12 ADP receptor antagonists can effectively reduce
1024 Y.-S. Lai et al.clopidogrel resistance among those having higher platelet
reactivity under clopidogrel therapy.5 Employing the new
antiplatelet agents, genetic analysis, and VerifyNow
platelet function test together, may provide a personal
tailored therapy strategy in those patients with high
thrombogenicity.
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